Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size was valued at US$ 97.8 million in 2022. With growing demand in downstream market, the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment is forecast to a readjusted size of US$ 208.4 million by 2029 with a CAGR of 11.4% during review period.
The research report highlights the growth potential of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disease caused by acquired somatic PIG-A gene (phosphotidyl inositol glycan complementation group A) mutations in one or several hematopoietic stem cells. Disease, PIG-A mutation causes abnormal synthesis of glycosyl phosphatidyl inositol (GPI), resulting in the loss of a group of membrane proteins anchored to the cell membrane by GPI, including CD16, CD55, CD59, etc., which are mainly clinically It manifests as chronic intravascular hemolysis, hematopoietic failure and recurrent thrombosis.
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a growing area focused on developing innovative drugs and treatments to improve the quality of life of patients with PNH. The market covers various treatment options, including monoclonal antibody therapies, immunosuppressive drugs, and hematopoietic stem cell transplantation, aimed at alleviating symptoms, controlling hemolysis, and improving blood abnormalities in PNH patients, thus providing better clinical outcomes. As scientific research continues to advance and medical technology continues to improve, the PNH treatment market is expected to continue to expand, providing patients with more treatment options and the opportunity to improve survival rates.
Key Features:
The report on Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It may include historical data, market segmentation by Type (e.g., Monoclonal Antibodies Therapy, Immunosuppressive Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry. This include advancements in Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment technology, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment new entrants, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment new investment, and other innovations that are shaping the future of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Market Segmentation:
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?
What factors are driving Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market opportunities vary by end market size?
How does Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment break out type, application?
According to our LPI (LP Information) latest study, the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size was valued at US$ 97.8 million in 2022. With growing demand in downstream market, the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment is forecast to a readjusted size of US$ 208.4 million by 2029 with a CAGR of 11.4% during review period.
The research report highlights the growth potential of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disease caused by acquired somatic PIG-A gene (phosphotidyl inositol glycan complementation group A) mutations in one or several hematopoietic stem cells. Disease, PIG-A mutation causes abnormal synthesis of glycosyl phosphatidyl inositol (GPI), resulting in the loss of a group of membrane proteins anchored to the cell membrane by GPI, including CD16, CD55, CD59, etc., which are mainly clinically It manifests as chronic intravascular hemolysis, hematopoietic failure and recurrent thrombosis.
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a growing area focused on developing innovative drugs and treatments to improve the quality of life of patients with PNH. The market covers various treatment options, including monoclonal antibody therapies, immunosuppressive drugs, and hematopoietic stem cell transplantation, aimed at alleviating symptoms, controlling hemolysis, and improving blood abnormalities in PNH patients, thus providing better clinical outcomes. As scientific research continues to advance and medical technology continues to improve, the PNH treatment market is expected to continue to expand, providing patients with more treatment options and the opportunity to improve survival rates.
Key Features:
The report on Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It may include historical data, market segmentation by Type (e.g., Monoclonal Antibodies Therapy, Immunosuppressive Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry. This include advancements in Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment technology, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment new entrants, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment new investment, and other innovations that are shaping the future of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.
Market Segmentation:
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Monoclonal Antibodies Therapy
- Immunosuppressive Drugs
- Hematopoietic Stem Cell Transplantation
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amoun Pharmaceuticals
- EIPICO
- Minapharm Pharmaceuticals
- Pharco Pharmaceuticals
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Akari Therapeutics
- Amgen
- CSL Behring
- Bioverativ
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Amgen Inc
- Teva Pharmaceutical
- Abbott
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?
What factors are driving Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market opportunities vary by end market size?
How does Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country/Region, 2018, 2022 & 2029
2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segment by Type
2.2.1 Monoclonal Antibodies Therapy
2.2.2 Immunosuppressive Drugs
2.2.3 Hematopoietic Stem Cell Transplantation
2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Type (2018-2023)
2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
2.5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Application (2018-2023)
3 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY COMPANY
3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Breakdown Data by Company
3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company (2018-2023)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Company (2018-2023)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Company
3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Location Distribution
3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
4.4 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
4.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
5 AMERICAS
5.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country
5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
5.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
5.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region
6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018-2023)
6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2018-2023)
6.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
6.3 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country
7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country
8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors
11.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer
12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY GEOGRAPHIC REGION
12.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Forecast by Region
12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Region (2024-2029)
12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Type
12.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amoun Pharmaceuticals
13.1.1 Amoun Pharmaceuticals Company Information
13.1.2 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.1.3 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amoun Pharmaceuticals Main Business Overview
13.1.5 Amoun Pharmaceuticals Latest Developments
13.2 EIPICO
13.2.1 EIPICO Company Information
13.2.2 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.2.3 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 EIPICO Main Business Overview
13.2.5 EIPICO Latest Developments
13.3 Minapharm Pharmaceuticals
13.3.1 Minapharm Pharmaceuticals Company Information
13.3.2 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.3.3 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Minapharm Pharmaceuticals Main Business Overview
13.3.5 Minapharm Pharmaceuticals Latest Developments
13.4 Pharco Pharmaceuticals
13.4.1 Pharco Pharmaceuticals Company Information
13.4.2 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.4.3 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pharco Pharmaceuticals Main Business Overview
13.4.5 Pharco Pharmaceuticals Latest Developments
13.5 Alexion Pharmaceuticals
13.5.1 Alexion Pharmaceuticals Company Information
13.5.2 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.5.3 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Alexion Pharmaceuticals Main Business Overview
13.5.5 Alexion Pharmaceuticals Latest Developments
13.6 Alnylam Pharmaceuticals
13.6.1 Alnylam Pharmaceuticals Company Information
13.6.2 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.6.3 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Alnylam Pharmaceuticals Main Business Overview
13.6.5 Alnylam Pharmaceuticals Latest Developments
13.7 Akari Therapeutics
13.7.1 Akari Therapeutics Company Information
13.7.2 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.7.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Akari Therapeutics Main Business Overview
13.7.5 Akari Therapeutics Latest Developments
13.8 Amgen
13.8.1 Amgen Company Information
13.8.2 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.8.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen Main Business Overview
13.8.5 Amgen Latest Developments
13.9 CSL Behring
13.9.1 CSL Behring Company Information
13.9.2 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.9.3 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 CSL Behring Main Business Overview
13.9.5 CSL Behring Latest Developments
13.10 Bioverativ
13.10.1 Bioverativ Company Information
13.10.2 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.10.3 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bioverativ Main Business Overview
13.10.5 Bioverativ Latest Developments
13.11 F. Hoffmann-La Roche Ltd
13.11.1 F. Hoffmann-La Roche Ltd Company Information
13.11.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.11.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.11.5 F. Hoffmann-La Roche Ltd Latest Developments
13.12 Novartis AG
13.12.1 Novartis AG Company Information
13.12.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.12.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis AG Main Business Overview
13.12.5 Novartis AG Latest Developments
13.13 Amgen Inc
13.13.1 Amgen Inc Company Information
13.13.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.13.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Amgen Inc Main Business Overview
13.13.5 Amgen Inc Latest Developments
13.14 Teva Pharmaceutical
13.14.1 Teva Pharmaceutical Company Information
13.14.2 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.14.3 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Teva Pharmaceutical Main Business Overview
13.14.5 Teva Pharmaceutical Latest Developments
13.15 Abbott
13.15.1 Abbott Company Information
13.15.2 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.15.3 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Abbott Main Business Overview
13.15.5 Abbott Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country/Region, 2018, 2022 & 2029
2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segment by Type
2.2.1 Monoclonal Antibodies Therapy
2.2.2 Immunosuppressive Drugs
2.2.3 Hematopoietic Stem Cell Transplantation
2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Type (2018-2023)
2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
2.5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Application (2018-2023)
3 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY COMPANY
3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Breakdown Data by Company
3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company (2018-2023)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Company (2018-2023)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Company
3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Location Distribution
3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
4.4 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
4.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth
5 AMERICAS
5.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country
5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
5.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
5.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region
6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018-2023)
6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2018-2023)
6.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
6.3 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country
7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Country
8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type
8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors
11.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer
12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT BY GEOGRAPHIC REGION
12.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Forecast by Region
12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Region (2024-2029)
12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Type
12.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amoun Pharmaceuticals
13.1.1 Amoun Pharmaceuticals Company Information
13.1.2 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.1.3 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amoun Pharmaceuticals Main Business Overview
13.1.5 Amoun Pharmaceuticals Latest Developments
13.2 EIPICO
13.2.1 EIPICO Company Information
13.2.2 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.2.3 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 EIPICO Main Business Overview
13.2.5 EIPICO Latest Developments
13.3 Minapharm Pharmaceuticals
13.3.1 Minapharm Pharmaceuticals Company Information
13.3.2 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.3.3 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Minapharm Pharmaceuticals Main Business Overview
13.3.5 Minapharm Pharmaceuticals Latest Developments
13.4 Pharco Pharmaceuticals
13.4.1 Pharco Pharmaceuticals Company Information
13.4.2 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.4.3 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pharco Pharmaceuticals Main Business Overview
13.4.5 Pharco Pharmaceuticals Latest Developments
13.5 Alexion Pharmaceuticals
13.5.1 Alexion Pharmaceuticals Company Information
13.5.2 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.5.3 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Alexion Pharmaceuticals Main Business Overview
13.5.5 Alexion Pharmaceuticals Latest Developments
13.6 Alnylam Pharmaceuticals
13.6.1 Alnylam Pharmaceuticals Company Information
13.6.2 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.6.3 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Alnylam Pharmaceuticals Main Business Overview
13.6.5 Alnylam Pharmaceuticals Latest Developments
13.7 Akari Therapeutics
13.7.1 Akari Therapeutics Company Information
13.7.2 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.7.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Akari Therapeutics Main Business Overview
13.7.5 Akari Therapeutics Latest Developments
13.8 Amgen
13.8.1 Amgen Company Information
13.8.2 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.8.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen Main Business Overview
13.8.5 Amgen Latest Developments
13.9 CSL Behring
13.9.1 CSL Behring Company Information
13.9.2 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.9.3 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 CSL Behring Main Business Overview
13.9.5 CSL Behring Latest Developments
13.10 Bioverativ
13.10.1 Bioverativ Company Information
13.10.2 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.10.3 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bioverativ Main Business Overview
13.10.5 Bioverativ Latest Developments
13.11 F. Hoffmann-La Roche Ltd
13.11.1 F. Hoffmann-La Roche Ltd Company Information
13.11.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.11.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.11.5 F. Hoffmann-La Roche Ltd Latest Developments
13.12 Novartis AG
13.12.1 Novartis AG Company Information
13.12.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.12.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis AG Main Business Overview
13.12.5 Novartis AG Latest Developments
13.13 Amgen Inc
13.13.1 Amgen Inc Company Information
13.13.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.13.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Amgen Inc Main Business Overview
13.13.5 Amgen Inc Latest Developments
13.14 Teva Pharmaceutical
13.14.1 Teva Pharmaceutical Company Information
13.14.2 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.14.3 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Teva Pharmaceutical Main Business Overview
13.14.5 Teva Pharmaceutical Latest Developments
13.15 Abbott
13.15.1 Abbott Company Information
13.15.2 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
13.15.3 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Abbott Main Business Overview
13.15.5 Abbott Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies Therapy
Table 4. Major Players of Immunosuppressive Drugs
Table 5. Major Players of Hematopoietic Stem Cell Transplantation
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Type (2018-2023) & ($ million)
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2018-2023)
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Application (2018-2023)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application (2018-2023)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Company (2018-2023) & (K Units)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company (2018-2023)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company (2018-2023)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Producing Area Distribution and Sales Area
Table 22. Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Products Offered
Table 23. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Geographic Region (2018-2023)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country/Region (2018-2023)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)
Table 35. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)
Table 36. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)
Table 38. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 40. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018-2023) & (K Units)
Table 41. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region (2018-2023)
Table 42. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Region (2018-2023)
Table 44. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 45. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)
Table 47. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)
Table 48. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)
Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Table 59. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Table 60. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Table 61. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors List
Table 64. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer List
Table 65. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Amoun Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 80. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 81. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Amoun Pharmaceuticals Main Business
Table 83. Amoun Pharmaceuticals Latest Developments
Table 84. EIPICO Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 85. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 86. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. EIPICO Main Business
Table 88. EIPICO Latest Developments
Table 89. Minapharm Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 90. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 91. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Minapharm Pharmaceuticals Main Business
Table 93. Minapharm Pharmaceuticals Latest Developments
Table 94. Pharco Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 95. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 96. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Pharco Pharmaceuticals Main Business
Table 98. Pharco Pharmaceuticals Latest Developments
Table 99. Alexion Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 100. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 101. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Alexion Pharmaceuticals Main Business
Table 103. Alexion Pharmaceuticals Latest Developments
Table 104. Alnylam Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 105. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 106. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Alnylam Pharmaceuticals Main Business
Table 108. Alnylam Pharmaceuticals Latest Developments
Table 109. Akari Therapeutics Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 110. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 111. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Akari Therapeutics Main Business
Table 113. Akari Therapeutics Latest Developments
Table 114. Amgen Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 115. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 116. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Amgen Main Business
Table 118. Amgen Latest Developments
Table 119. CSL Behring Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 120. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 121. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. CSL Behring Main Business
Table 123. CSL Behring Latest Developments
Table 124. Bioverativ Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 125. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 126. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Bioverativ Main Business
Table 128. Bioverativ Latest Developments
Table 129. F. Hoffmann-La Roche Ltd Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 130. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 131. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. F. Hoffmann-La Roche Ltd Main Business
Table 133. F. Hoffmann-La Roche Ltd Latest Developments
Table 134. Novartis AG Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 135. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 136. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Novartis AG Main Business
Table 138. Novartis AG Latest Developments
Table 139. Amgen Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 140. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 141. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Amgen Inc Main Business
Table 143. Amgen Inc Latest Developments
Table 144. Teva Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 145. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 146. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Teva Pharmaceutical Main Business
Table 148. Teva Pharmaceutical Latest Developments
Table 149. Abbott Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 150. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 151. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Abbott Main Business
Table 153. Abbott Latest Developments
Table 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies Therapy
Table 4. Major Players of Immunosuppressive Drugs
Table 5. Major Players of Hematopoietic Stem Cell Transplantation
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Type (2018-2023) & ($ million)
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2018-2023)
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Application (2018-2023)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application (2018-2023)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Company (2018-2023) & (K Units)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company (2018-2023)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company (2018-2023)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Producing Area Distribution and Sales Area
Table 22. Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Products Offered
Table 23. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Geographic Region (2018-2023)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country/Region (2018-2023)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)
Table 35. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)
Table 36. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)
Table 38. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 40. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018-2023) & (K Units)
Table 41. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region (2018-2023)
Table 42. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Region (2018-2023)
Table 44. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 45. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)
Table 47. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)
Table 48. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)
Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Table 59. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Table 60. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Table 61. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors List
Table 64. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer List
Table 65. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Amoun Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 80. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 81. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Amoun Pharmaceuticals Main Business
Table 83. Amoun Pharmaceuticals Latest Developments
Table 84. EIPICO Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 85. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 86. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. EIPICO Main Business
Table 88. EIPICO Latest Developments
Table 89. Minapharm Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 90. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 91. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Minapharm Pharmaceuticals Main Business
Table 93. Minapharm Pharmaceuticals Latest Developments
Table 94. Pharco Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 95. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 96. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Pharco Pharmaceuticals Main Business
Table 98. Pharco Pharmaceuticals Latest Developments
Table 99. Alexion Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 100. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 101. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Alexion Pharmaceuticals Main Business
Table 103. Alexion Pharmaceuticals Latest Developments
Table 104. Alnylam Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 105. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 106. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Alnylam Pharmaceuticals Main Business
Table 108. Alnylam Pharmaceuticals Latest Developments
Table 109. Akari Therapeutics Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 110. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 111. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Akari Therapeutics Main Business
Table 113. Akari Therapeutics Latest Developments
Table 114. Amgen Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 115. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 116. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Amgen Main Business
Table 118. Amgen Latest Developments
Table 119. CSL Behring Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 120. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 121. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. CSL Behring Main Business
Table 123. CSL Behring Latest Developments
Table 124. Bioverativ Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 125. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 126. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Bioverativ Main Business
Table 128. Bioverativ Latest Developments
Table 129. F. Hoffmann-La Roche Ltd Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 130. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 131. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. F. Hoffmann-La Roche Ltd Main Business
Table 133. F. Hoffmann-La Roche Ltd Latest Developments
Table 134. Novartis AG Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 135. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 136. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Novartis AG Main Business
Table 138. Novartis AG Latest Developments
Table 139. Amgen Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 140. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 141. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Amgen Inc Main Business
Table 143. Amgen Inc Latest Developments
Table 144. Teva Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 145. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 146. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Teva Pharmaceutical Main Business
Table 148. Teva Pharmaceutical Latest Developments
Table 149. Abbott Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 150. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolios and Specifications
Table 151. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Abbott Main Business
Table 153. Abbott Latest Developments
LIST OF FIGURES
Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Figure 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Monoclonal Antibodies Therapy
Figure 10. Product Picture of Immunosuppressive Drugs
Figure 11. Product Picture of Hematopoietic Stem Cell Transplantation
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type in 2022
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2018-2023)
Figure 14. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Hospital
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Hospital (2018-2023) & (K Units)
Figure 16. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Clinic
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Clinic (2018-2023) & (K Units)
Figure 18. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Other
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Other (2018-2023) & (K Units)
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2022)
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application in 2022
Figure 22. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market by Company in 2022 (K Units)
Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company in 2022
Figure 24. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company in 2022
Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 29. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 30. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 31. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 36. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022
Figure 37. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022
Figure 38. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 40. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region in 2022
Figure 45. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Regions in 2022
Figure 46. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 47. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 48. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022
Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022
Figure 57. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 58. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 59. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 68. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment in 2022
Figure 74. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Figure 75. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Figure 76. Channels of Distribution
Figure 77. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Forecast by Region (2024-2029)
Figure 78. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Figure 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Monoclonal Antibodies Therapy
Figure 10. Product Picture of Immunosuppressive Drugs
Figure 11. Product Picture of Hematopoietic Stem Cell Transplantation
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type in 2022
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2018-2023)
Figure 14. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Hospital
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Hospital (2018-2023) & (K Units)
Figure 16. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Clinic
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Clinic (2018-2023) & (K Units)
Figure 18. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Consumed in Other
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Other (2018-2023) & (K Units)
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2022)
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application in 2022
Figure 22. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market by Company in 2022 (K Units)
Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Company in 2022
Figure 24. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Company in 2022
Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 29. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 30. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 31. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2018-2023 ($ Millions)
Figure 36. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022
Figure 37. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022
Figure 38. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 40. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region in 2022
Figure 45. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Regions in 2022
Figure 46. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 47. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 48. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022
Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022
Figure 57. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 58. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 59. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2018-2023)
Figure 68. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment in 2022
Figure 74. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Figure 75. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Figure 76. Channels of Distribution
Figure 77. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Forecast by Region (2024-2029)
Figure 78. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share Forecast by Application (2024-2029)
